BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide derived from a protein found in gastric juice. It has accumulated a substantial preclinical research literature over 30+ years, primarily from research groups at the University of Zagreb. Here is what the published evidence actually shows — and what it doesn’t.
What Is BPC-157?
BPC-157 is a pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). It is a partial sequence of human Body Protection Compound (BPC), which is present in gastric juice. The synthetic version is highly stable — resistant to degradation in both aqueous solution and in biological fluids, which distinguishes it from many other peptides.
Gastrointestinal Research
The earliest and most extensive published research focused on GI mucosal protection and healing. Published rodent studies report accelerated healing of gastric ulcers, intestinal anastomosis wounds, and esophageal damage. The proposed mechanisms include upregulation of growth factors (EGF, bFGF, VEGF) and modulation of nitric oxide synthesis pathways.
A 2015 study in World Journal of Gastroenterology reported that BPC-157 counteracted NSAID-induced GI damage in rat models, with effects attributed to NO-system modulation. The compound has been investigated as a potential GI cytoprotective agent across multiple published papers.
Musculoskeletal and Tendon Research
A substantial body of rodent research examines BPC-157 in musculoskeletal contexts. Published studies report improved tendon-to-bone healing in Achilles tendon transection models, accelerated muscle crush injury recovery, and improved bone fracture healing timelines in rat models.
The proposed mechanisms involve upregulation of the growth hormone receptor system locally, increased collagen synthesis, and angiogenic effects. Notably, published data suggests BPC-157 may modulate the GH-receptor expression at injury sites — a mechanism that differs from systemic GH secretagogues.
The Human Data Gap
This is the critical limitation: as of 2025, there is only one completed registered human clinical trial for BPC-157. NCT02637284 was a Phase IIa oral safety study for inflammatory bowel disease (PLD-116, a BPC-157 analogue by PL BioScience GmbH). The trial enrolled 24 participants and assessed safety, not efficacy. Full results have not been published in a peer-reviewed journal as of this writing.
All tissue repair, musculoskeletal, and neurological research is rodent-model only. The translational gap from rodent to human for peptide compounds is significant — many compounds that perform well in rodent models do not replicate in human trials.
Neurological and CNS Research
More recent published research has examined CNS applications. Rodent studies report effects on dopaminergic system recovery following neurotoxic insult, counteraction of certain drug-induced movement disorders, and neuroprotective effects in brain injury models. The proposed mechanism involves the interaction between BPC-157 and the dopaminergic, serotonergic, and GABAergic systems — though the exact pathways remain incompletely characterized.
Evidence Level Summary
- GI mucosal protection: Strong preclinical evidence (rodent); no published human efficacy data
- Tendon/muscle healing: Moderate-strong preclinical evidence; no human data
- Bone healing: Moderate preclinical evidence; no human data
- Neurological protection: Early preclinical evidence; hypothesis-generating only
- Human safety: One Phase II safety study (oral route, IBD indication); results unpublished
Research Use Context
BPC-157 is not approved by the FDA or EMA for any therapeutic indication. It is classified as research use only (RUO). Anyone studying this compound should review applicable regulatory requirements for their jurisdiction. This article is educational context only.
Study Design Limitations Worth Naming Directly
Beyond the concentration-in-one-lab issue discussed in our general BPC-157 overview, the specific preclinical studies underlying these findings have design characteristics that temper how confidently their results should be extrapolated. Rodent group sizes in this literature are typically small (often single-digit to low-double-digit animals per group), which limits statistical power to detect anything but large effects and makes replication by other labs especially important — and comparatively rare, as previously noted. Many of the foundational papers also predate more recent, stricter reporting standards for preclinical research (such as the ARRIVE guidelines for animal study reporting, first published in 2010 and revised in 2020), meaning blinding, randomization, and sample-size justification are not always described in the level of detail expected of contemporary preclinical publications. None of this means the findings are wrong — it means the evidentiary weight of any individual study in this body of literature is more modest than “published in a peer-reviewed journal” alone might suggest.
Beyond Tendon and Gut: CNS and Toxic-Injury Research
Beyond the gastrointestinal and musculoskeletal research most commonly discussed, the Sikiric group’s published work also extends into central nervous system contexts, including studies reporting BPC-157 effects on dopamine and serotonin system function in various rodent injury and behavioral models, and a separate line of research examining protective effects against alcohol-induced, corticosteroid-induced, and NSAID-induced gastrointestinal and hepatic injury. These findings extend the compound’s proposed protective/healing profile beyond tissue repair specifically into broader organ-protective and neurochemical contexts, though — consistent with the rest of the BPC-157 literature — they remain preclinical (rodent-model) findings without completed human trial confirmation.
Frequently Asked Questions
Are the rodent studies behind BPC-157’s tendon healing claims large, well-powered trials?
Generally no — most rodent group sizes in this literature are small, which is standard for exploratory preclinical mechanism studies but means individual studies carry less statistical weight than the volume of published papers might suggest.
Does BPC-157’s CNS research mean it has been studied as a treatment for depression or anxiety?
The published research examines effects on neurotransmitter systems (dopamine, serotonin) in specific animal injury and behavioral models — this is mechanistic preclinical research, not clinical trial evidence for any human psychiatric indication.
What are ARRIVE guidelines and why do they matter here?
ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines are a reporting standard meant to improve the rigor and reproducibility of published animal research; many older BPC-157 papers predate the most current version of these standards, which is a relevant methodological consideration when weighing the literature’s overall quality.
Key References
- Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157. Curr Pharm Des. 2011;17(16):1554-66.
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-80.
- Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.
